| MeSH term | MeSH ID | Detail |
|---|---|---|
| Adenocarcinoma | D000230 | 166 associated lipids |
| Lupus Erythematosus, Systemic | D008180 | 43 associated lipids |
| Lung Neoplasms | D008175 | 171 associated lipids |
| Pancreatic Neoplasms | D010190 | 77 associated lipids |
| Colonic Neoplasms | D003110 | 161 associated lipids |
| Mammary Neoplasms, Experimental | D008325 | 67 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
| Edema | D004487 | 152 associated lipids |
| Precancerous Conditions | D011230 | 48 associated lipids |
| Prostatic Neoplasms | D011471 | 126 associated lipids |
2E,6E-farnesol
2e,6e-farnesol is a lipid of Prenol Lipids (PR) class. 2e,6e-farnesol is associated with abnormalities such as Granulomatous Disease, Chronic, pathologic fistula and Cavitation. The involved functions are known as Regulation, Metabolic Inhibition, cholesterol biosynthetic process, Process and Transcription, Genetic. 2e,6e-farnesol often locates in Plasma membrane, Cytoplasmic matrix, cornified envelope, Epidermis and peroxisome. The associated genes with 2E,6E-farnesol are RAB3A gene, FOSL1 gene, CASP8AP2 gene, RCC1 gene and GALE gene. The related lipids are Sterols, Membrane Lipids and Steroids.
Cross Reference
Introduction
To understand associated biological information of 2E,6E-farnesol, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with 2E,6E-farnesol?
2E,6E-farnesol is suspected in Granulomatous Disease, Chronic, pathologic fistula and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with 2E,6E-farnesol
PubChem Associated disorders and diseases
What pathways are associated with 2E,6E-farnesol
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with 2E,6E-farnesol?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with 2E,6E-farnesol?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with 2E,6E-farnesol?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with 2E,6E-farnesol?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with 2E,6E-farnesol?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with 2E,6E-farnesol
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Hornby JM et al. | Quorum sensing in the dimorphic fungus Candida albicans is mediated by farnesol. | 2001 | Appl. Environ. Microbiol. | pmid:11425711 |
| Schlitzer M and Dahse HM | Structure activity relationship of antiproliferative N-acyl-beta-alanine amides. | 2000 Nov-Dec | Anticancer Res. | pmid:11205283 |
| Hartmann MA et al. | Metabolism of farnesyl diphosphate in tobacco BY-2 cells treated with squalestatin. | 2000 | Biochem. Soc. Trans. | pmid:11171211 |
| Beedle AM and Zamponi GW | Block of voltage-dependent calcium channels by aliphatic monoamines. | 2000 | Biophys. J. | pmid:10866952 |
| Mo H et al. | Farnesyl anthranilate suppresses the growth, in vitro and in vivo, of murine B16 melanomas. | 2000 | Cancer Lett. | pmid:10936674 |
| Toró A et al. | Transannular Diels-Alder studies on the asymmetric total synthesis of chatancin: the pyranophane approach. | 2000 | Org. Lett. | pmid:10964353 |
| Yang W et al. | Protein farnesylation is critical for maintaining normal cell morphology and canavanine resistance in Schizosaccharomyces pombe. | 2000 | J. Biol. Chem. | pmid:10617635 |
| Hanley K et al. | Farnesol stimulates differentiation in epidermal keratinocytes via PPARalpha. | 2000 | J. Biol. Chem. | pmid:10753967 |
| Bringmann A et al. | Farnesol modulates membrane currents in human retinal glial cells. | 2000 | J. Neurosci. Res. | pmid:11054809 |
| Halaschek-Wiener J et al. | A novel Ras antagonist regulates both oncogenic Ras and the tumor suppressor p53 in colon cancer cells. | 2000 | Mol. Med. | pmid:11055588 |
| Xie H et al. | Synthesis and biological evaluation of the geometric farnesylated analogues of the a-factor mating peptide of Saccharomyces cerevisiae. | 2000 | J. Org. Chem. | pmid:11112575 |
| Eskens FA et al. | Farnesyl transferase inhibitors: current developments and future perspectives. | 2000 | Cancer Treat. Rev. | pmid:11006134 |
| Kloog Y and Cox AD | RAS inhibitors: potential for cancer therapeutics. | 2000 | Mol Med Today | pmid:11006529 |
| Hemmerlin A and Bach TJ | Farnesol-induced cell death and stimulation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity in tobacco cv bright yellow-2 cells. | 2000 | Plant Physiol. | pmid:10938345 |
| González-Coloma A et al. | Structure- and species-dependent insecticidal effects of neo-clerodane diterpenes. | 2000 | J. Agric. Food Chem. | pmid:10956169 |
| Mussoni L et al. | Fluvastatin inhibits basal and stimulated plasminogen activator inhibitor 1, but induces tissue type plasminogen activator in cultured human endothelial cells. | 2000 | Thromb. Haemost. | pmid:10928471 |
| Rioja A et al. | Preferential induction of apoptosis of leukaemic cells by farnesol. | 2000 | FEBS Lett. | pmid:10675556 |
| Hemmer W et al. | Axillary dermatitis from farnesol in a deodorant. | 2000 | Contact Derm. | pmid:10727172 |
| Rosado JA and Sage SO | Farnesylcysteine analogues inhibit store-regulated Ca2+ entry in human platelets: evidence for involvement of small GTP-binding proteins and actin cytoskeleton. | 2000 | Biochem. J. | pmid:10727417 |
| Flach J et al. | The mevalonate/isoprenoid pathway inhibitor apomine (SR-45023A) is antiproliferative and induces apoptosis similar to farnesol. | 2000 | Biochem. Biophys. Res. Commun. | pmid:10733934 |
| Girgert R et al. | Inhibition of farnesyl-protein-transferase in neuroblastoma cells by alpha-hydroxyfarnesylphosphonate. | 1999 Jul-Aug | Anticancer Res. | pmid:10652579 |
| Anthony ML et al. | Inhibition of phosphatidylcholine biosynthesis following induction of apoptosis in HL-60 cells. | 1999 | J. Biol. Chem. | pmid:10391908 |
| Andres DA et al. | Rapid identification of cysteine-linked isoprenyl groups by metabolic labeling with [3H]farnesol and [3H]geranylgeraniol. | 1999 | Methods Mol. Biol. | pmid:10399149 |
| Dudler T and Gelb MH | Probing the role of H-Ras lipidation for signaling functions in Xenopus laevis oocytes. | 1999 | Methods Mol. Biol. | pmid:10399152 |
| Bifulco M et al. | Inhibition of farnesylation blocks growth but not differentiation in FRTL-5 thyroid cells. | 1999 | Biochimie | pmid:10401660 |
| Weisz B et al. | A new functional Ras antagonist inhibits human pancreatic tumor growth in nude mice. | 1999 | Oncogene | pmid:10353601 |
| Egozi Y et al. | Growth inhibition of ras-dependent tumors in nude mice by a potent ras-dislodging antagonist. | 1999 | Int. J. Cancer | pmid:10074926 |
| Machida K et al. | Farnesol-induced growth inhibition in Saccharomyces cerevisiae by a cell cycle mechanism. | 1999 | Microbiology (Reading, Engl.) | pmid:10075411 |
| Fisher JE et al. | Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. | 1999 | Proc. Natl. Acad. Sci. U.S.A. | pmid:9874784 |
| Parmryd I and Dallner G | In vivo prenylation of rat proteins: modification of proteins with penta- and hexaprenyl groups. | 1999 | Arch. Biochem. Biophys. | pmid:10190969 |
| Luft UC et al. | Farnesol blocks the L-type Ca2+ channel by targeting the alpha 1C subunit. | 1999 | Arterioscler. Thromb. Vasc. Biol. | pmid:10195923 |
| Roullet JB et al. | Modulation of neuronal voltage-gated calcium channels by farnesol. | 1999 | J. Biol. Chem. | pmid:10464274 |
| Parmryd I et al. | Protein prenylation in spinach chloroplasts. | 1999 | Proc. Natl. Acad. Sci. U.S.A. | pmid:10468564 |
| Gibbs BS et al. | Novel farnesol and geranylgeraniol analogues: A potential new class of anticancer agents directed against protein prenylation. | 1999 | J. Med. Chem. | pmid:10508429 |
| Ghosh PM et al. | Role of RhoA activation in the growth and morphology of a murine prostate tumor cell line. | 1999 | Oncogene | pmid:10435593 |
| Benford HL et al. | Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. | 1999 | Mol. Pharmacol. | pmid:10385693 |
| Lin HP et al. | Localization of isoprenylated antigen of hepatitis delta virus by anti-farnesyl antibodies. | 1999 | J. Gen. Virol. | pmid:9934689 |
| Niv H et al. | Membrane interactions of a constitutively active GFP-Ki-Ras 4B and their role in signaling. Evidence from lateral mobility studies. | 1999 | J. Biol. Chem. | pmid:9880539 |
| Weissmann N et al. | Evidence for a role of protein kinase C in hypoxic pulmonary vasoconstriction. | 1999 | Am. J. Physiol. | pmid:9887060 |
| Hanley K et al. | Fetal epidermal differentiation and barrier development In vivo is accelerated by nuclear hormone receptor activators. | 1999 | J. Invest. Dermatol. | pmid:10571735 |
| Goodwin TE et al. | African elephant sesquiterpenes. | 1999 | J. Nat. Prod. | pmid:10579877 |
| Machida K and Tanaka T | Farnesol-induced generation of reactive oxygen species dependent on mitochondrial transmembrane potential hyperpolarization mediated by F(0)F(1)-ATPase in yeast. | 1999 | FEBS Lett. | pmid:10580101 |
| Hirohata S et al. | Inhibition of human B cell activation by a novel nonsteroidal anti-inflammatory drug, indometacin famesil. | 1999 | Immunopharmacology | pmid:10598881 |
| Jansen B et al. | Farnesylthiosalicylic acid inhibits the growth of human Merkel cell carcinoma in SCID mice. | 1999 | J. Mol. Med. | pmid:10619439 |
| Yasugi E | [Induction of apoptosis by isoprenoids]. | 1999 | Seikagaku | pmid:10659677 |
| Shack S et al. | Activation of the cholesterol pathway and Ras maturation in response to stress. | 1999 | Oncogene | pmid:10557091 |
| Thai L et al. | Farnesol is utilized for isoprenoid biosynthesis in plant cells via farnesyl pyrophosphate formed by successive monophosphorylation reactions. | 1999 | Proc. Natl. Acad. Sci. U.S.A. | pmid:10557276 |
| Jansen B et al. | Novel Ras antagonist blocks human melanoma growth. | 1999 | Proc. Natl. Acad. Sci. U.S.A. | pmid:10570191 |
| Elad G et al. | Targeting of K-Ras 4B by S-trans,trans-farnesyl thiosalicylic acid. | 1999 | Biochim. Biophys. Acta | pmid:10590312 |
| Reif S et al. | The Ras antagonist, farnesylthiosalicylic acid (FTS), inhibits experimentally-induced liver cirrhosis in rats. | 1999 | J. Hepatol. | pmid:10604579 |
| Corsini A et al. | Incorporation of radiolabeled prenyl alcohols and their analogs into mammalian cell proteins. A useful tool for studying protein prenylation. | 1999 | Methods Mol. Biol. | pmid:10399150 |
| Vaidya S et al. | Massive production of farnesol-derived dicarboxylic acids in mice treated with the squalene synthase inhibitor zaragozic acid A. | 1998 | Arch. Biochem. Biophys. | pmid:9647670 |
| Hohl RJ et al. | Stereochemistry-dependent inhibition of RAS farnesylation by farnesyl phosphonic acids. | 1998 | Lipids | pmid:9470172 |
| Aharonson Z et al. | Stringent structural requirements for anti-Ras activity of S-prenyl analogues. | 1998 | Biochim. Biophys. Acta | pmid:9545527 |
| Ura H et al. | Selective cytotoxicity of farnesylamine to pancreatic carcinoma cells and Ki-ras-transformed fibroblasts. | 1998 | Mol. Carcinog. | pmid:9496909 |
| Haklai R et al. | Dislodgment and accelerated degradation of Ras. | 1998 | Biochemistry | pmid:9477957 |
| Hampton RY | Genetic analysis of hydroxymethylglutaryl-coenzyme A reductase regulated degradation. | 1998 | Curr. Opin. Lipidol. | pmid:9559264 |
| Desrosiers RR and Béliveau R | Regulation by GTPgammaS of protein carboxylmethyltransferase activity in kidney brush border membranes. | 1998 | Arch. Biochem. Biophys. | pmid:9514644 |
| Miquel K et al. | Competitive inhibition of choline phosphotransferase by geranylgeraniol and farnesol inhibits phosphatidylcholine synthesis and induces apoptosis in human lung adenocarcinoma A549 cells. | 1998 | J. Biol. Chem. | pmid:9748300 |
| Laezza C et al. | v-K-ras leads to preferential farnesylation of p21(ras) in FRTL-5 cells: multiple interference with the isoprenoid pathway. | 1998 | Proc. Natl. Acad. Sci. U.S.A. | pmid:9811854 |
| Ferdinandy P et al. | Rapid pacing-induced preconditioning is recaptured by farnesol treatment in hearts of cholesterol-fed rats: role of polyprenyl derivatives and nitric oxide. | 1998 | Mol. Cell. Biochem. | pmid:9774182 |
| Shipman CM et al. | The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. | 1998 | Cancer Res. | pmid:9850051 |
| Aboushadi N and Krisans SK | Analysis of isoprenoid biosynthesis in peroxisomal-deficient Pex2 CHO cell lines. | 1998 | J. Lipid Res. | pmid:9741690 |
| Bentinger M et al. | Phosphorylation of farnesol in rat liver microsomes: properties of farnesol kinase and farnesyl phosphate kinase. | 1998 | Arch. Biochem. Biophys. | pmid:9606952 |
| Nishio E et al. | Alpha1-adrenoreceptor stimulation causes vascular smooth muscle cell hypertrophy: a possible role for isoprenoid intermediates. | 1998 | Eur. J. Pharmacol. | pmid:9650858 |
| Szilvassy Z et al. | Improvement of nitrergic relaxation by farnesol of the sphincter of Oddi from hypercholesterolaemic rabbits. | 1998 | Eur. J. Pharmacol. | pmid:9721042 |
| Machida K et al. | Farnesol-induced generation of reactive oxygen species via indirect inhibition of the mitochondrial electron transport chain in the yeast Saccharomyces cerevisiae. | 1998 | J. Bacteriol. | pmid:9721283 |
| Strickland CL et al. | Crystal structure of farnesyl protein transferase complexed with a CaaX peptide and farnesyl diphosphate analogue. | 1998 | Biochemistry | pmid:9843427 |
| Rajab MS et al. | Antimycobacterial activity of (E)-phytol and derivatives: a preliminary structure-activity study. | 1998 | Planta Med. | pmid:9491760 |
| Llorente-Cortés V et al. | Esterified cholesterol accumulation induced by aggregated LDL uptake in human vascular smooth muscle cells is reduced by HMG-CoA reductase inhibitors. | 1998 | Arterioscler. Thromb. Vasc. Biol. | pmid:9598832 |
| Pérez-Sala D et al. | Analogs of farnesylcysteine induce apoptosis in HL-60 cells. | 1998 | FEBS Lett. | pmid:9600259 |
| Rubins JB et al. | Lovastatin induces apoptosis in malignant mesothelioma cells. | 1998 | Am. J. Respir. Crit. Care Med. | pmid:9603146 |
| Crick DC et al. | Geranylgeraniol overcomes the block of cell proliferation by lovastatin in C6 glioma cells. | 1998 | J. Neurochem. | pmid:9603204 |
| Pei ZM et al. | Role of farnesyltransferase in ABA regulation of guard cell anion channels and plant water loss. | 1998 | Science | pmid:9765153 |
| Iazlovitskaia EM et al. | Human leukemia CEM C-1 cells possess a high affinity binding site for farnesol. | 1997 Mar-Apr | Ukr. Biokhim. Zh. | pmid:9463231 |
| Bostedor RG et al. | Farnesol-derived dicarboxylic acids in the urine of animals treated with zaragozic acid A or with farnesol. | 1997 | J. Biol. Chem. | pmid:9083051 |
| Roullet JB et al. | Inhibition of Ca2+ uptake into A7r5 vascular smooth muscle cells by farnesol: lack of effect on membrane fluidity and Ca2+-ATPase activities. | 1997 | J. Hypertens. | pmid:9488229 |
| Roullet JB et al. | Farnesol inhibits L-type Ca2+ channels in vascular smooth muscle cells. | 1997 | J. Biol. Chem. | pmid:9405427 |
| Kogo Y and kato J | [Malignant tumor and apoptosis]. | 1997 | Nippon Naika Gakkai Zasshi | pmid:9410963 |
| Nozawa Y et al. | Stachybotrin C and parvisporin, novel neuritogenic compounds. II. Structure determination. | 1997 | J. Antibiot. | pmid:9315075 |
| Saisho Y et al. | Determination of farnesyl pyrophosphate in dog and human plasma by high-performance liquid chromatography with fluorescence detection. | 1997 | Anal. Biochem. | pmid:9324945 |
| Noonan DJ and O'Brien ML | A hypothetical mechanism for fat-induced rodent hepatocarcinogenesis. | 1997 | Adv. Exp. Med. Biol. | pmid:9361820 |
| Gana-Weisz M et al. | The Ras antagonist S-farnesylthiosalicylic acid induces inhibition of MAPK activation. | 1997 | Biochem. Biophys. Res. Commun. | pmid:9367867 |
| Goossens A and Merckx L | Allergic contact dermatitis from farnesol in a deodorant. | 1997 | Contact Derm. | pmid:9385513 |
| Meigs TE and Simoni RD | Farnesol as a regulator of HMG-CoA reductase degradation: characterization and role of farnesyl pyrophosphatase. | 1997 | Arch. Biochem. Biophys. | pmid:9281305 |
| Takaichi S et al. | The major carotenoid in all known species of heliobacteria is the C30 carotenoid 4,4'-diaponeurosporene, not neurosporene. | 1997 | Arch. Microbiol. | pmid:9297464 |
| Crick DC et al. | Novel salvage pathway utilizing farnesol and geranylgeraniol for protein isoprenylation. | 1997 | Biochem. Biophys. Res. Commun. | pmid:9299388 |
| Van Dessel G et al. | Internalisation of short-chain isoprenyl diphosphates by chromaffin cells from bovine adrenal medulla. | 1997 | Biochem. Biophys. Res. Commun. | pmid:9299441 |
| Blazer-Yost BL et al. | Protein prenylation is required for aldosterone-stimulated Na+ transport. | 1997 | Am. J. Physiol. | pmid:9227422 |
| Crick DC et al. | Geranylgeraniol promotes entry of UT-2 cells into the cell cycle in the absence of mevalonate. | 1997 | Exp. Cell Res. | pmid:9087171 |
| Leitner JW et al. | Hyperinsulinemia potentiates activation of p21Ras by growth factors. | 1997 | Endocrinology | pmid:9112423 |
| Flint OP et al. | Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro. | 1997 | Toxicol. Appl. Pharmacol. | pmid:9221828 |
| Denda M et al. | Epidermal injury stimulates prenylation in the epidermis of hairless mice. | 1997 | Arch. Dermatol. Res. | pmid:9049045 |
| Tamone SL et al. | Identification and characterization of methyl farnesoate binding proteins from the crab, Cancer magister. | 1997 | Gen. Comp. Endocrinol. | pmid:9038249 |
| Westfall D et al. | Metabolism of farnesol: phosphorylation of farnesol by rat liver microsomal and peroxisomal fractions. | 1997 | Biochem. Biophys. Res. Commun. | pmid:9015362 |
| Ghosh PM et al. | Lovastatin induces apoptosis by inhibiting mitotic and post-mitotic events in cultured mesangial cells. | 1997 | Biochim. Biophys. Acta | pmid:9398081 |
| Zhang L et al. | Isolation and characterization of a prenylcysteine lyase from bovine brain. | 1997 | J. Biol. Chem. | pmid:9287348 |
| Andres DA et al. | Expression cloning of a novel farnesylated protein, RDJ2, encoding a DnaJ protein homologue. | 1997 | Arch. Biochem. Biophys. | pmid:9328291 |
| Meigs TE et al. | Regulation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase degradation by the nonsterol mevalonate metabolite farnesol in vivo. | 1996 | J. Biol. Chem. | pmid:8626470 |
| O'Brien ML et al. | Convergence of three steroid receptor pathways in the mediation of nongenotoxic hepatocarcinogenesis. | 1996 | Carcinogenesis | pmid:8625436 |